A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients

Grants and Contracts Details

StatusFinished
Effective start/end date6/20/071/31/09

Funding

  • Novartis (domestic): $10,573.00